Madrigal Pharmaceuticals
Quarterly Financials
| Values in thousands | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
|---|---|---|---|---|
Revenue | $62,175 | $14,638 | $0 | $770 |
Gross Profit | 60,023 | 13,735 | -168 | 628 |
EBITDA | -102,987 | -148,048 | -143,535 | -108,081 |
EBIT | -103,285 | -148,315 | -143,703 | -108,223 |
Net Income | -106,964 | -151,971 | -147,541 | -112,194 |
Net Change In Cash | 62,175 | 14,638 | 0 | 770 |
Free Cash Flow | -67,763 | -140,076 | -149,514 | -80,969 |
Cash | 232,684 | 499,597 | 622,517 | 99,915 |
Basic Shares | 21,745 | 21,402 | 20,001 | 19,760 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $37 | $21 |
Gross Profit | -527 | -467 | 273 | 21 |
EBITDA | -379,969 | -293,104 | -242,077 | -206,202 |
EBIT | -380,496 | -293,571 | -242,482 | -206,673 |
Net Income | -373,630 | -299,314 | -241,078 | -197,444 |
Net Change In Cash | 0 | 0 | 37 | 21 |
Cost of Revenue | 295,280 | -17,735 | 7,307 | |
Free Cash Flow | -325,709 | -225,074 | -184,126 | -157,895 |
Cash | 99,915 | 331,549 | 36,269 | 54,004 |
Basic Shares | 18,687 | 17,137 | 16,535 | 15,446 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-09-30 | -$4.92 |
2024-06-30 | -$7.10 |
2024-03-31 | -$7.38 |
2023-12-31 | -$5.68 |
